Recommendation of the President – Raxone (idebenone)

On 22 May 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 66/2025 on the validity of granting approval for the reimbursement of a medicinal product Raxone (idebenone) in the indication: Leber hereditary optic neuropathy in pediatric patients – continuation of treatment in which the patient has benefited

Publication in Public Information Bulletin (BIP) >>